REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On July 28, 2026, the FDA released briefing documents regarding the Company’s lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents revealed the FDA has deemed the single-armed mid-stage study submitted by Replimune to support the drug’s approval as “non interpretable.” FDA reviewers stated the assessment used in the study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results.”
